Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus HCC1806rPCL20 (CVCL_D6VI)

[Text version]
Cell line name HCC1806rPCL20
Synonyms HCC1806 rPaclitaxel20
Accession CVCL_D6VI
Resource Identification Initiative To cite this cell line use: HCC1806rPCL20 (RRID:CVCL_D6VI)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: African American.
Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
Derived from site: In situ; Breast; UBERON=UBERON_0000310.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Thr256Lysfs*90 (c.766_767insAA); Zygosity=Heterozygous (from parent cell line).
Disease Breast squamous cell carcinoma, acantholytic variant (NCIt: C40359)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1258 (HCC1806)
Sex of cell Female
Age at sampling 60Y
Category Cancer cell line
Publications

DOI=10.1101/2024.01.20.576412
Grimsley H.E., Antczak M., McLaughlin K.-M., Nist A., Mernberger M., Stiewe T., Speidel D., Cox K., Cinatl J. Jr., Wass M.N., Garrett M.D., Michaelis M.
Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors.
bioRxiv 2024:01.20.576412-01.20.576412(2024)

Entry history
Entry creation10-Sep-2024
Last entry update10-Sep-2024
Version number1